Donisi Health Overview
Donisi Health is a medical technology company providing user-friendly in-home health detection solutions for patients with congestive heart failure (CHF) and other chronic diseases. Donisi enables a user-friendly preemptive approach to cardiac and pulmonary health monitoring in the home, helping to optimize the continuum of care for patients with CHF and other chronic diseases and avoid unnecessary rehospitalization. Based on Donisi's FDA-cleared technology and backed by 11 granted patents, Donisi's contact-free health detection works free from wires, wearables, and patches. The company's patented AI-based system detects and analyzes multiple health bio-indicators simultaneously, delivering clinically meaningful insights and notifications of changes in key health indicators. Donisi's clinically validated contact-free technology can remotely detect signs of pulmonary congestion and additional parameters key for heart failure exacerbation detection in the home.
Cumulative Funding Raised Over Time ($)
—
—Jun 2022
$20.0MMar 2018
$27.0MMay 2016
$27.0MOct 2022
Latest News
growth-positive
Donisi Health Gets FDA's De Novo Clearance for Its Gili Biosensor System
Donisi Health has received FDA authorization to market its Gili biosensor system. The device uses an optical sensor and software algorithms to gather and analyze video data to estimate pulse rate, heart rate, respiratory rate, and breathing rates. The system is indicated for use by healthcare professionals in medical care settings or for clinical research purposes. The FDA has classified the device as hardware and software for optical camera-based measurement of vital signs.
Customers
growth-positive
Study Demonstrates Efficacy of Contact-Free Tech for Pulmonary Congestion Detection at Home
Donisi Health, a MedTech company, announced the results of a clinical study demonstrating the efficacy of its contact-free technology for detecting pulmonary congestion in congestive heart failure (CHF) patients. The study, presented at the American College of Cardiologys annual Scientific Session, showed that Donisis remote monitoring solution can detect key health biomarkers such as pulmonary congestion at home, potentially preventing unnecessary hospital readmissions. The study assessed Donisis Gili Pro BioSensor, which achieved a sensitivity and specificity of 0.91 and an accuracy of 91%. The companys AI-based technology can provide medical-grade monitoring for pulmonary congestion, offering a novel approach for at-home monitoring. The study was conducted in collaboration with the Department of Cardiology at the Tel Aviv Sourasky Medical Center.
Customers
growth-positive
Donisi Health Presents Data at ACC22 Demonstrating Accuracy of a Contact-Free Medical Device that Detects Pulmonary Congestion in CHF Patients at Home
Donisi Health, a MedTech company, announced the results of a clinical study demonstrating the efficacy of its contact-free technology for detecting pulmonary congestion in congestive heart failure (CHF) patients. The study presented at the American College of Cardiologys annual Scientific Session showed that Donisis remote monitoring solution could detect key health biomarkers such as pulmonary congestion at home, potentially preventing unnecessary patient re-hospitalization. The study confirmed that Donisis contact-free infrared optical solution could provide medical-grade monitoring for pulmonary congestion, offering a novel approach for at-home monitoring of CHF patients. Donisis technology detects and analyzes multiple health bio-indicators simultaneously, providing a platform solution for managing patients with multiple chronic conditions and co-morbidities. The company plans to expand the clinical scope of its technology and seek clearance for at-home identification of pulmonary congestion.
Customers
growth-positive
Israeli startup Donisi Health lands De Novo for AI-enabled contactless monitor
Donisi Health, a Tel Aviv-based maker of contactless health monitoring products, has received FDA De Novo clearance for its Gili Pro BioSensor system. The system uses optical sensors and AI algorithms to remotely monitor surface-level micro-vibrations associated with the workings of internal organs. Donisi plans to expand the clinical scope of the Gili Pro and has already undergone the FDA Pre Submission process for the identification of atrial fibrillation. The company aims to bridge the continuum of care from hospital to home. The Gili Pro has maintained medical-grade accuracy across different body shapes and skin tones. The device can be controlled through a mobile application. The prospect of remote continuous vital-sign monitoring is especially desirable amid the pandemic. Donisis technology is recognized and cleared by the FDA.
Expand
growth-positive
250 companies and $6.5 billion: An in-depth look at Israel's healthtech industry
Israeli healthcare startups are reinventing business models and elevating the industry. The article discusses the growth and innovation in the Israeli healthcare startup ecosystem. It highlights the key areas of Digital Health, Medical Devices, and Biopharma, and how these sectors are evolving their business models. Digital Health startups are shifting towards providing end-to-end solutions, while Medical Device startups are adapting to the Value Based Care model. Biopharma startups are focusing on precision medicine and drug R&D. The article emphasizes the growth and value generated by Israeli healthcare startups, with a combined funding of $6.5 billion. The analysis was conducted by Pitango HealthTech Fund.
CustomersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $27.2M |
| Last funding | Undisclosed |
| Stage | B |
| Rounds | 6 |
| Investors | 5 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | donisihealth.com/ |
| Careers | Careers page |
| App Store | App Store |
Locations
HaNechoshet Street 6, Tel Aviv, Israel
California, USA
Photos & Videos
3 item(s)
Donisi Health Business
Business models
B2B2C
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical MonitorsDigital HealthcarePatient Remote MonitoringTarget Customer
Healthcare & Life SciencesMedical Devices IndustryHealthcarePatientsProvidersConsumersDemographics & FamilySeniorsCore Technology
Platforms & InterfacesMobileSensingAcousticsVibrationBiometricsArtificial IntelligenceDeep LearningMachine LearningTags (28)
medical-devicessensorsbiometricsmhealthchronic-patientsmonitoringnon-invasivechronic-diseaseseniorsclinicsautomotiveelectro-opticsdigital-healthcarenanotechnologyremote-monitoringvital-signshealthcare-providersinsurance-companiestelemedicinepulmonaryoptronicsmedical-technologiescompliancerespiratorycardiovascularartificial-intelligencesafetyheart-failureGeographic Markets
EuropeUnited StatesDonisi Health Financials
$27.2M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
B
Funding stage
6
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
—
—Jun 2022
$20.0MMar 2018
$27.0MMay 2016
$27.0MOct 2022
Private Equity Funding
Convertible Debt
Oct 2022
Undisclosed
The Chartered Group
Convertible Debt
Jun 2022
Undisclosed
The Chartered Group
B Round
Mar 2018
$20M
The Chartered Group (Lead)
,
OTV
Seed
May 2016
$7M
Johnson Controls, Lenovo Group, OTV
Undisclosed Round
Undisclosed
Kli Capital
Non-Equity Funding
GrantEvent
Dec 2021
$200K
Donisi Health Lifecycle
Cumulative Funding Raised Over Time
—
—Jun 2022
$20.0MMar 2018
$27.0MMay 2016
$27.0MOct 2022
All Events
Convertible Debt
Oct 2022
Undisclosed
The Chartered Group
Convertible Debt
Jun 2022
Undisclosed
The Chartered Group
B Round
Mar 2018
$20M
The Chartered Group (Lead)
,
OTV
Seed
May 2016
$7M
Johnson Controls, Lenovo Group, OTV
Undisclosed Round
Undisclosed
Kli Capital
GrantEvent
Dec 2021
$200K
Donisi Health News
13 articles
growth-positive
Donisi Health Gets FDA's De Novo Clearance for Its Gili Biosensor System
Donisi Health has received FDA authorization to market its Gili biosensor system. The device uses an optical sensor and software algorithms to gather and analyze video data to estimate pulse rate, heart rate, respiratory rate, and breathing rates. The system is indicated for use by healthcare professionals in medical care settings or for clinical research purposes. The FDA has classified the device as hardware and software for optical camera-based measurement of vital signs.
Customers
growth-positive
Study Demonstrates Efficacy of Contact-Free Tech for Pulmonary Congestion Detection at Home
Donisi Health, a MedTech company, announced the results of a clinical study demonstrating the efficacy of its contact-free technology for detecting pulmonary congestion in congestive heart failure (CHF) patients. The study, presented at the American College of Cardiologys annual Scientific Session, showed that Donisis remote monitoring solution can detect key health biomarkers such as pulmonary congestion at home, potentially preventing unnecessary hospital readmissions. The study assessed Donisis Gili Pro BioSensor, which achieved a sensitivity and specificity of 0.91 and an accuracy of 91%. The companys AI-based technology can provide medical-grade monitoring for pulmonary congestion, offering a novel approach for at-home monitoring. The study was conducted in collaboration with the Department of Cardiology at the Tel Aviv Sourasky Medical Center.
Customers
growth-positive
Donisi Health Presents Data at ACC22 Demonstrating Accuracy of a Contact-Free Medical Device that Detects Pulmonary Congestion in CHF Patients at Home
Donisi Health, a MedTech company, announced the results of a clinical study demonstrating the efficacy of its contact-free technology for detecting pulmonary congestion in congestive heart failure (CHF) patients. The study presented at the American College of Cardiologys annual Scientific Session showed that Donisis remote monitoring solution could detect key health biomarkers such as pulmonary congestion at home, potentially preventing unnecessary patient re-hospitalization. The study confirmed that Donisis contact-free infrared optical solution could provide medical-grade monitoring for pulmonary congestion, offering a novel approach for at-home monitoring of CHF patients. Donisis technology detects and analyzes multiple health bio-indicators simultaneously, providing a platform solution for managing patients with multiple chronic conditions and co-morbidities. The company plans to expand the clinical scope of its technology and seek clearance for at-home identification of pulmonary congestion.
Customers
growth-positive
Israeli startup Donisi Health lands De Novo for AI-enabled contactless monitor
Donisi Health, a Tel Aviv-based maker of contactless health monitoring products, has received FDA De Novo clearance for its Gili Pro BioSensor system. The system uses optical sensors and AI algorithms to remotely monitor surface-level micro-vibrations associated with the workings of internal organs. Donisi plans to expand the clinical scope of the Gili Pro and has already undergone the FDA Pre Submission process for the identification of atrial fibrillation. The company aims to bridge the continuum of care from hospital to home. The Gili Pro has maintained medical-grade accuracy across different body shapes and skin tones. The device can be controlled through a mobile application. The prospect of remote continuous vital-sign monitoring is especially desirable amid the pandemic. Donisis technology is recognized and cleared by the FDA.
Expand
growth-positive
250 companies and $6.5 billion: An in-depth look at Israel's healthtech industry
Israeli healthcare startups are reinventing business models and elevating the industry. The article discusses the growth and innovation in the Israeli healthcare startup ecosystem. It highlights the key areas of Digital Health, Medical Devices, and Biopharma, and how these sectors are evolving their business models. Digital Health startups are shifting towards providing end-to-end solutions, while Medical Device startups are adapting to the Value Based Care model. Biopharma startups are focusing on precision medicine and drug R&D. The article emphasizes the growth and value generated by Israeli healthcare startups, with a combined funding of $6.5 billion. The analysis was conducted by Pitango HealthTech Fund.
CustomersInvestment
growth-positive
Diagnostics and Sensing: minature sensors and cameras are helping revolutionize patient treatment
Bio-convergence, the combination of engineering and bio-medical applications, is facilitating the development of innovative medical technologies. One such technology is a non-invasive treatment for monitoring the development of Alzheimers, developed by Prof. Zeev Zalevsky at Bar Ilan University. Other developments include an enhanced CT system, high-resolution endoscope imaging, and a technology for remote medical diagnosis. MeMed, a company backed by leading venture capital funds in the US and Asia, has developed a 15-minute blood test that can identify the cause of an infection, helping to reduce unnecessary prescription of antibiotics.
InvestmentCustomers
growth-positive
Here's how Continuse Biometrics works
Continuse Biometrics, a startup working in the space of preventive care for cardiovascular diseases and diabetes, is developing a unique nano technology-based bio-sensor. The bio-sensor can monitor and diagnose over 20 biomedical parameters, including heart and respiration rates and blood pressure.
Customers
growth-positive
Medical monitoring co ContinUse Biometrics raises $20m
ContinUse Biometrics, an Israeli company specializing in AI-based sensing solutions for healthcare, has raised $20 million in a Series B financing round led by the Chartered Group. The company has raised a total of $27 million to date. ContinUse Biometrics is partnering with leaders in healthcare, automotive, and data analytics to develop an innovative care solution that allows users to detect early deterioration in their medical conditions. The companys product can also be used for monitoring driver alertness and competence to enhance road safety. Founded in 2015, ContinUse Biometrics applies advanced AI techniques to analyze collected data in its health cloud, providing actionable insights for patients and physicians in various medical areas.
Investment
growth-positive
Tech Can Alleviate Pressure on Hospitals, Says ContinUse Biometrics CTO
Zeev Zalevsky, the CTO of ContinUse Biometrics, spoke at a digital and mobile conference in Tel Aviv. He discussed how the healthcare industry is struggling to keep up with patient demand and how advanced technology can help ease the pressure on doctors. ContinUse Biometrics has developed a sensor that can measure patients physical health at the molecular level and translate the data into medical parameters. The sensor, designed for smartphones, allows users to monitor their health at home and reduce pressure on healthcare providers. The sensor is set to become available in the first quarter of 2018.
CustomersExpand
growth-positive
Measuring a patient's vital signs without any contact
ContinUse Biometrics, a company founded by Zeev Zalevsky and Javier Garcia-Monreal, has developed a revolutionary way to monitor patients vital signs without physical contact. Their product consists of a laser and camera system that can detect nano-vibrations emitted by the body. The company has raised funds from Lenovo, Tyco, and Olive Tree Ventures. The sensor can monitor various vital signs and is ideal for telemedicine. ContinUse Biometrics aims to set up a monitoring system for patients at home, saving costs and providing convenience. The low manufacturing costs of the sensor make it suitable for developing countries. The company plans to partner with major players in the consumer electronics field. The product is expected to be available by the end of 2017.
CustomersPartnersInvestment
growth-positive
Tyco invests in Israeli sensor co ContinUse Biometrics
ContinUse Biometrics, an Israeli startup, has received a strategic investment from Tyco, a global security corporation. The investment, estimated to be around $1 million, will allow ContinUse Biometrics to further develop its biometric sensor technology and integrate it into solutions for the construction and smart home industries. The sensor is capable of remotely detecting and monitoring various physiological signs without contact, such as heart rate, blood pressure, and glucose levels. It can be used for identity authentication, access control, and operational supervision. ContinUse Biometrics was founded in 2015 and has also received investments from Lenovo and Olive Tree Venture Fund. The investment from Tyco demonstrates confidence in the companys disruptive technology and its potential for global presence.
InvestmentPartners
growth-positive
ContinUse Biometrics receives strategic investment from Tyco Biometric Update
ContinUse Biometrics has received a million dollar strategic investment from Tyco, allowing them to further develop their contactless biometric sensor platform. The investment will also enable the embedding of the technology into solutions for Tycos clients worldwide. ContinUse Biometrics platform can monitor various bio parameters from a distance, including heart and respiratory rate, blood flow dynamics, and muscle activity. This opens up opportunities in markets such as identification and authentication, bio-competence monitoring, and healthcare. Tycos investment is a vote of confidence in ContinUse Biometrics disruptive capabilities in the biometrics industry. Other investors in the company include Lenovo and Olive Tree Venture Fund.
Investment
http://www.geektime.com/2015/10/21/gtc2015-bar-ilan-professor-revolutionizes-diagnostics-with-new-company/
Donisi Health Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 8 |
| Team members | 8 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 22 classification IDs that could be used for matching.
Donisi Health Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515223949 |
| Crunchbase | donisi-health |
| Phone | +972775215560 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-10-27T00:00:00.000Z |
| Created | 2014-08-20T00:00:00.000Z |